p53 orchestrates between normal differentiation and cancer.

Keywords

Political science

References

• Heterogeneity in cancer: cancer stem cells versus clonal evolution.Irma Northland Leppe, Pedro Jara‐Seguel, Natalia Celis — 2009
• Mechanisms maintaining genomic integrity in embryonic stem cells and induced pluripotent stem cellsElisia D. Tichy — 2011
• Wild type p53 functions as a control protein in the differentiation pathway of the B-cell lineage.Ronit Aloni-Grinstein, Israel Zan‐Bar, I Alboum — 1993
• The tumorigenicity of human embryonic stem cells.Barak Blum, Nissim Benvenisty — 2008
• mdm2 expression is induced by wild type p53 activity.Yaacov Barak, T. Juven, Rebecca Haffner — 1993
• Alterations in tumor development in vivo mediated by expression of wild type or mutant p53 proteins.Gad Shaulsky, Naomi Goldfinger, V Rotter — 1991
• DNA damage-induced neural precursor cell apoptosis requires p53 and caspase 9 but neither Bax nor caspase 3.Cleta D’Sa-Eipper, Jeffrey R. Leonard, Girish Putcha — 2001
• Expression of p53 during mouse embryogenesis.Peter Schmid, Andreas Lorenz, H. Hameister — 1991
• p53 plays a regulatory role in differentiation and apoptosis of central nervous system-associated cellsOrly Eizenberg, Anat Faber‐Elman, Eyal Gottlieb — 1996
• Epithelial-mesenchymal transitions in development and disease.Jean Paul Thiery, Hervé Acloque, Ruby Yun‐Ju Huang — 2009
• NANOG promotes cancer stem cell characteristics and prostate cancer resistance to androgen deprivationCollene Jeter, Bigang Liu, Xin Liu — 2011
• Snail and Slug Mediate Radioresistance and Chemoresistance by Antagonizing p53‐Mediated Apoptosis and Acquiring a Stem‐Like Phenotype in Ovarian Cancer CellsNawneet K. Kurrey, Swati Jalgaonkar, Alok V. Joglekar — 2009
• The first 30 years of p53: growing ever more complexArnold J. Levine, Moshe Oren — 2009
• Distinct regulatory mechanisms and functions of p53-activated and p53-repressed DNA damage response genes in embryonic stem cellsMangmang Li, Yunlong He, Wendy Dubois — 2012
• The tumorigenicity of human embryonic and induced pluripotent stem cellsUri Ben‐David, Nissim Benvenisty — 2011
• Activation of p53 by nutlin leads to rapid differentiation of human embryonic stem cellsToivo Maimets, Irina Neganova, Lyle Armstrong — 2008
• The canals of hering and hepatic stem cells in humansNeil D. Theise, Romil Saxena, Bernard Portmann — 1999
• When mutants gain new powers: news from the mutant p53 fieldRan Brosh, Varda Rotter — 2009
• Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53Roberto Montes de Oca Luna, Daniel S. Wagner, Guillermina Lozano — 1995
• Regulation of p53 in embryonic stem cells.Valeria Solozobova, Christine Blattner — 2010

Cited by

• X-ray and ultraviolet C irradiation-induced γ-H2AX and p53 formation in normal human periosteal cells in vitro: markers for quality control in cell therapy.Anna Carlstedt — 2015
• DNA Damage in Stem Cells.Carlos Aguilar Paredes — 2017
• The p53-Mdm2 loop: a critical juncture of stress response.Yaara Levav-Cohen, Zehavit Goldberg, Kah Hin Tan — 2014
• New perspective on targeting the tumor suppressor p53 pathway in the tumor microenvironment to enhance the efficacy of immunotherapyGang Guo, Yan Cui — 2015
• Significance of apoptosis related proteins on malignant transformation of ovarian tumors: A comparison between Bcl-2/Bax ratio and p53 immunoreactivity.Tamer Zeren, Sevinç İnan, Seda Vatansever — 2014
• p53 suppression partially rescues the mutant phenotype in mouse models of DiGeorge syndromeCinzia Caprio, Antonio Baldini — 2014
• The paradigm of mutant p53-expressing cancer stem cells and drug resistance.Yoav Shetzer, Hilla Solomon, Gabriela Koifman — 2014
• Targeting Oncogenic Mutant p53 for Cancer TherapyAlejandro Parrales, Tomoo Iwakuma — 2015
• P53 functional abnormality in mesenchymal stem cells promotes osteosarcoma developmentTania Velletri, N Xie, Ying Wang — 2016
• Oncogenic Mutant p53 Gain of Function Nourishes the Vicious Cycle of Tumor Development and Cancer Stem-Cell Formation.Yoav Shetzer, Alina Molchadsky, Varda Rotter — 2016
• FoxO proteins or loss of functional p53 maintain stemness of glioblastoma stem cells and survival after ionizing radiation plus PI3K/mTOR inhibitionElke Firat, Gabriele Niedermann — 2016
• Clinical Outcomes of TP53 Mutations in Cancers.Ana I. Robles, Jin Jen, Curtis C. Harris — 2016
• Lysine methylation represses p53 activity in teratocarcinoma cancer cellsJiajun Zhu, Zhixun Dou, Morgan A. Sammons — 2016
• DNAJA1 controls the fate of misfolded mutant p53 through the mevalonate pathwayAlejandro Parrales, Atul Ranjan, Swathi V. Iyer — 2016
• The testis-specific USP26 is a deubiquitinating enzyme of the ubiquitin ligase Mdm2.Shirly Lahav‐Baratz, Yelena Kravtsova‐Ivantsiv, Shay Golan — 2017
• Immunomodulatory Function of the Tumor Suppressor p53 in Host Immune Response and the Tumor MicroenvironmentYan Cui, Gang Guo — 2016
• Differential regulated microRNA by wild type and mutant p53 in induced pluripotent stem cellsFrancesca Grespi, Vivien Landré, Alina Molchadsky — 2016
• Treatments for EGFR‐mutant non‐small cell lung cancer (NSCLC): The road to a success, paved with failuresKi Hyeong Lee — 2017
• DNA-damage response in hematopoietic stem cells: an evolutionary trade-off between blood regeneration and leukemia suppression.Shahar Biechonski, Muhammad Yassin, Michael Milyavsky — 2017
• p53 and its mutants on the slippery road from stemness to carcinogenesis.Alina Molchadsky, Varda Rotter — 2017

Related papers

No related papers recorded.